Recent studies revealed that MALT1 is a promising therapeutic target for the treatment of ABC-DLBCL. Among several reported MALT1 inhibitors, MI-2 as an irreversible inhibitor represents a new class of ABC-DLBCL therapeutics. Due to its inherent potential cross-reactivity, further structure-activity relationship (SAR) study is imperative. In this work, five focused compound libraries based on the chemical structure of MI-2 are designed and synthesized. The systematic SARs revealed that the side chain of 2-methoxyethoxy has little impact on the activity and can be replaced by other functionalized groups, providing new MI-2 analogues with retained or enhanced potency. Compounds 81-83 with terminal hydroxyl group as side chain displayed enhanced activities against MALT1. Replacement of triazole core with pyrazole is also tolerant, while structural modifications on other sites are detrimental. These findings will facilitate further development of small-molecule MALT1 inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2018.04.059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression.
bioRxiv
September 2024
Department of Pediatrics, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
MALT1 protease is an intracellular signaling molecule that promotes tumor progression via cancer cell-intrinsic and cancer cell-extrinsic mechanisms. MALT1 has been mostly studied in lymphocytes, and little is known about its role in tumor-associated macrophages. Here, we show that MALT1 plays a key role in glioblastoma (GBM)-associated macrophages.
View Article and Find Full Text PDFRapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
In silico study of some plant compounds as potential anticancer agents targeting MALT1 allosteric domain.
J Biomol Struct Dyn
September 2024
Department of Biochemistry, Federal University of Technology, Akure, Ondo State, Nigeria.
Article Synopsis
- MALT1 is a crucial protein involved in immune responses, and its unusual signaling is linked to various diseases, including cancer, making it a target for new therapies.
- The study aimed to identify plant-based small molecules that could bind to MALT1 using computational methods, screening 34 compounds for their effectiveness.
- Cyanidin emerged as a promising allosteric inhibitor of MALT1, showing better binding and stability than the control drug thioridazine, but further testing is necessary to confirm its effectiveness in treating cancer and related diseases.
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.
ACS Med Chem Lett
September 2024
Smith, Gambrell & Russell LLP, 1105 West Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
Provided herein are novel MALT1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer and immunological diseases and processes for preparing such compounds.
View Article and Find Full Text PDFBlood MALT1 serves as a potential biomarker reflecting the response and survival of immune‑checkpoint‑inhibitor therapy in advanced hepatocellular carcinoma.
Oncol Lett
October 2024
Department of Gastroenterology, Handan Central Hospital, Handan, Hebei 056000, P.R. China.
Article Synopsis
- Scientists are studying a new treatment option for a type of liver cancer called hepatocellular carcinoma (HCC) that helps boost the immune system.
- They want to see if a protein called MALT1 found in blood could help predict how well patients respond to the treatment and how long they might live.
- Results showed that patients with higher levels of MALT1 had worse treatment results and shorter survival times compared to those with lower levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!